Allogene Therapeutics Inc (ALLO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
David D. Chang
Employees:
330
689 5TH AVENUE, 12TH FLOOR, NEW YORK, NY 10022
212-871-7920

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Data derived from most recent annual or quarterly report
Market Cap 712.398 Million Shares Outstanding144.21 Million Avg 30-day Volume 1.972 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.58
Price to Revenue52.6499 Debt to Equity0.0 EBITDA-248.265 Million
Price to Book Value2.2113 Operating Margin-664.5847 Enterprise Value1.199 Billion
Current Ratio9.784 EPS Growth0 Quick Ratio9.493
1 Yr BETA 1.5498 52-week High/Low 17.49 / 4.83 Profit Margin-667.7362
Operating Cash Flow Growth-60.5762 Altman Z-Score8.4338 Free Cash Flow to Firm -224.213 Million
Earnings Report2023-05-03
View SEC Filings from ALLO instead.

View recent insider trading info

Allogene Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ALLO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALLO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-24 by MOORE ALISON
  • 4: filed on 2023-03-24 by SCHMIDT ERIC THOMAS
  • 4: filed on 2023-03-24 by ROBERTS ZACHARY
  • 4: filed on 2023-03-24 by BELLDEGRUN ARIE
  • 4: filed on 2023-03-24 by CHANG DAVID D
  • 4: filed on 2023-03-16 by CHANG DAVID D
  • 4: filed on 2023-03-16 by SCHMIDT ERIC THOMAS
  • 4: filed on 2023-03-16 by MOORE ALISON
  • 4: filed on 2023-03-16 by BHAVNAGRI VEER
  • 4: filed on 2023-02-14 by BHAVNAGRI VEER

    • Events (8k)

  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-11-29:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-06:
    Item 8.01: Other Events
  • 8-K: filed on 2022-09-21:
    Item 8.01: Other Events
  • 8-K: filed on 2022-07-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    3 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BELLDEGRUN ARIE

    • Director
    		 8,358,208 2023-03-22 1

    CHANG DAVID D PRESIDENT AND CEO

    • Officer
    • Director
    		 6,251,063 2023-03-22 2

    SCHMIDT ERIC THOMAS CHIEF FINANCIAL OFFICER

    • Officer
    		 2,015,034 2023-03-22 2

    MOORE ALISON CHIEF TECHNICAL OFFICER

    • Officer
    		 672,731 2023-03-22 2

    ROBERTS ZACHARY EVP OF R&D

    • Officer
    		 399,943 2023-03-22 3

    BHAVNAGRI VEER GENERAL COUNSEL

    • Officer
    		 556,049 2023-03-14 4

    AMADO RAFAEL EVP OF R&D

    • Officer
    		 541,946 2022-10-07 6

    WITTE OWEN N.

    • Director
    		 218,271 2022-08-11 4

    MAYO STEPHEN

    • Director
    		 0 2022-07-08 2

    SATO VICKI L

    • Director
    		 76,986 2022-06-15 1

    KAZAM JOSHUA A

    • Director
    		 303,063 2022-06-15 1

    HUMER FRANZ B

    • Director
    		 191,892 2022-06-15 1

    MESSEMER DEBORAH M.

    • Director
    		 77,605 2022-06-15 1

    BARRETT ELIZABETH A.

    • Director
    		 71,070 2022-06-15 1

    PF EQUITY HOLDINGS 2 B.V.

    • 10% Owner
    		 0 2022-03-31 0

    TPG GP A, LLC

    WINKELRIED JON

    • 10% Owner
    		 18,716,306 2022-01-12 0

    TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

    BONDERMAN DAVID

    COULTER JAMES G

    • Director
    • 10% Owner
    		 18,716,306 2020-08-06 0

    PFIZER INC

    • 10% Owner
    		 22,032,040 2018-10-15 0

    SISITSKY TODD BENJAMIN

    • Director
    		 0 2018-10-10 0

    DEYOUNG JOHN A.

    • Director
    		 0 2018-10-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    CHANG DAVID D - Director - Officer PRESIDENT AND CEO

    		2023-03-24 20:13:19 -0400 2023-03-22 A 1,492,200 a 1,492,200 direct

    CHANG DAVID D - Director - Officer PRESIDENT AND CEO

    		2023-03-24 20:13:19 -0400 2023-03-22 A 1,924,464 a 4,193,911 direct -2.1869 0.0 1 -2.1869 2

    BELLDEGRUN ARIE - Director

    		2023-03-24 20:14:49 -0400 2023-03-22 A 994,800 a 994,800 direct

    BELLDEGRUN ARIE - Director

    		2023-03-24 20:14:49 -0400 2023-03-22 A 1,282,976 a 1,654,886 direct -2.1869 0.0 1 -2.1869 2

    ROBERTS ZACHARY - Officer EVP OF R&D

    		2023-03-24 20:16:40 -0400 2023-03-22 A 148,035 a 399,943 direct -2.1869 0.0 1 -2.1869 2

    SCHMIDT ERIC THOMAS - Officer CHIEF FINANCIAL OFFICER

    		2023-03-24 20:17:56 -0400 2023-03-22 A 432,738 a 432,738 direct

    SCHMIDT ERIC THOMAS - Officer CHIEF FINANCIAL OFFICER

    		2023-03-24 20:17:56 -0400 2023-03-22 A 558,094 a 862,439 direct -2.1869 0.0 1 -2.1869 2

    MOORE ALISON - Officer CHIEF TECHNICAL OFFICER

    		2023-03-24 20:19:18 -0400 2023-03-22 A 432,738 a 432,738 direct

    MOORE ALISON - Officer CHIEF TECHNICAL OFFICER

    		2023-03-24 20:19:18 -0400 2023-03-22 A 558,094 a 672,731 direct -2.1869 0.0 1 -2.1869 2

    BHAVNAGRI VEER - Officer GENERAL COUNSEL

    		2023-03-16 16:46:11 -0400 2023-03-14 F 23,628 $5.67 d 556,049 direct -2.1858 -8.561 0.0 1 -8.561 6

    MOORE ALISON - Officer CHIEF TECHNICAL OFFICER

    		2023-03-16 16:49:16 -0400 2023-03-14 F 8,351 $5.51 d 114,637 direct -2.1858 -8.561 0.0 1 -8.561 6

    SCHMIDT ERIC THOMAS - Officer CHIEF FINANCIAL OFFICER

    		2023-03-16 17:08:11 -0400 2023-03-14 F 35,879 $5.47 d 304,345 direct -2.1858 -8.561 0.0 1 -8.561 6

    CHANG DAVID D - Director - Officer PRESIDENT AND CEO

    		2023-03-16 17:32:26 -0400 2023-03-14 F 22,340 $5.56 d 2,269,447 direct -2.1858 -8.561 0.0 1 -8.561 6

    BHAVNAGRI VEER - Officer GENERAL COUNSEL

    		2023-02-14 17:10:36 -0500 2023-02-13 S 3,000 $6.85 d 577,677 direct yes -3.0429 -10.2351 -31.2586 0.0 1 -31.9502 29

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 22:15:04 UTC 4.3441 0.4759 200000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 21:45:05 UTC 4.3441 0.4759 200000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 21:15:03 UTC 4.3441 0.4759 200000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 20:45:04 UTC 4.3441 0.4759 200000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 20:15:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 19:45:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 19:15:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 18:45:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 18:15:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 17:45:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 17:15:03 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 16:45:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 16:15:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 15:45:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 15:15:03 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 14:45:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 14:15:04 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 13:45:03 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 13:15:03 UTC 4.4355 0.3845 100000
    ALLOGENE THERAPEUTICS INC ALLO 2023-03-31 12:45:03 UTC 4.4355 0.3845 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund ALLO -87.0 shares, $-3280.77 2020-09-30 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund ALLO -80.0 shares, $-1555.2 2020-03-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund ALLO -44.0 shares, $-1659.24 2020-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund ALLO -161.0 shares, $-3129.84 2020-03-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund ALLO -2326.0 shares, $-43007.74 2021-11-30 N-PORT
    RBB Fund, Inc.- Boston Partners Long/Short Research Fund ALLO -71985.0 shares, $-709772.1 2022-11-30 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund ALLO -1016.0 shares, $-6390.64 2022-12-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments